Literature DB >> 28243797

Investigation into the association between P2RX7 gene polymorphisms and susceptibility to primary gout and hyperuricemia in a Chinese Han male population.

Ying Ying1, Yong Chen2, Zhen Li1, Haiyan Huang1, Qiongyao Gong1.   

Abstract

The purpose of this study was to investigate the relationship between P2RX7 gene single nucleotide polymorphisms and primary gout and hyperuricemia in a Chinese Han male population. The genetic distributions of the single nucleotide polymorphisms (SNPs) rs2230911, rs208294, rs435309, rs28360447, rs1718119, rs28360457, and rs3751143 in P2RX7 were detected in 293 primary gout patients, 187 hyperuricemia patients and 269 controls using SNaPshot technology. Statistical analyses were implemented using SPSS version 20.0. The genetic distributions of each group were tested for Hardy-Weinberg equilibrium (HWE). T test, analysis of variance, rank sum test and Chi-square test were measured to assess differences in clinical data and polymorphisms among groups. Logistic regression was used to assess susceptibility to disease with odds ratios (ORs) and 95% confidence intervals (95% CIs). SHEsis software was used to calculate linkage disequilibrium blocks and haplotype association risk. P < .05 was regarded as statistically significant. Three SNPs (rs2230911, rs208294 and rs435309) did not deviate significantly from HWE (P > .05). In the comparison between primary gout and control, the frequencies of rs2230911 genotypes were significantly different (P = .002), and allele G was associated with a higher risk of primary gout than allele C [OR (95% CI) = 1.755 (1.278, 2.410), P < .001]. There was also a higher risk of primary gout in genotype (CG + GG) compared with genotype CC [OR (95% CI) = 1.876 (1.303, 2.701), P = .001]. However, no significant difference in allelic or genotypic frequency was observed between primary gout patients and hyperuricemia patients (P > .0167). Similarly, there were no obvious differences in the other two polymorphisms among the three groups (P > .05). Our results reveal that P2RX7 rs2230911 may be associated with primary gout risk in a Chinese Han male population and allele G may be a susceptibility factor for primary gout.

Entities:  

Keywords:  Hyperuricemia; P2RX7; Polymorphism; Primary gout; SNP

Mesh:

Substances:

Year:  2017        PMID: 28243797     DOI: 10.1007/s00296-017-3669-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  37 in total

Review 1.  Nucleotide receptors: an emerging family of regulatory molecules in blood cells.

Authors:  F Di Virgilio; P Chiozzi; D Ferrari; S Falzoni; J M Sanz; A Morelli; M Torboli; G Bolognesi; O R Baricordi
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

2.  Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion.

Authors:  Leanne Stokes; Stephen J Fuller; Ronald Sluyter; Kristen K Skarratt; Ben J Gu; James S Wiley
Journal:  FASEB J       Date:  2010-04-01       Impact factor: 5.191

3.  Gain-of-function of P2X7 receptor gene variants in multiple sclerosis.

Authors:  Olatz Oyanguren-Desez; Alfredo Rodríguez-Antigüedad; Pablo Villoslada; María Domercq; Elena Alberdi; Carlos Matute
Journal:  Cell Calcium       Date:  2011-09-08       Impact factor: 6.817

4.  A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes.

Authors:  Giulio Cabrini; Simonetta Falzoni; Sylvia L Forchap; Patrizia Pellegatti; Alessandra Balboni; Paola Agostini; Antonio Cuneo; Gianluigi Castoldi; O Roberto Baricordi; Francesco Di Virgilio
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

5.  A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages.

Authors:  Anne N Shemon; Ronald Sluyter; Suran L Fernando; Alison L Clarke; Lan-Phuong Dao-Ung; Kristen K Skarratt; Bernadette M Saunders; Khai See Tan; Ben J Gu; Stephen J Fuller; Warwick J Britton; Steven Petrou; James S Wiley
Journal:  J Biol Chem       Date:  2005-11-01       Impact factor: 5.157

Review 6.  The P2X7 receptor: a key player in IL-1 processing and release.

Authors:  Davide Ferrari; Cinzia Pizzirani; Elena Adinolfi; Roberto M Lemoli; Antonio Curti; Marco Idzko; Elisabeth Panther; Francesco Di Virgilio
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

7.  An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor.

Authors:  Ben J Gu; Ronald Sluyter; Kristen K Skarratt; Anne N Shemon; Lan-Phuong Dao-Ung; Stephen J Fuller; Julian A Barden; Alison L Clarke; Steven Petrou; James S Wiley
Journal:  J Biol Chem       Date:  2004-04-27       Impact factor: 5.157

Review 8.  P2X7R: a potential key regulator of acute gouty arthritis.

Authors:  Jin-Hui Tao; Yong Zhang; Xiang-Pei Li
Journal:  Semin Arthritis Rheum       Date:  2013-06-17       Impact factor: 5.532

Review 9.  An update on the genetic architecture of hyperuricemia and gout.

Authors:  Tony R Merriman
Journal:  Arthritis Res Ther       Date:  2015-04-10       Impact factor: 5.156

10.  The P2X(7) loss-of-function Glu496Ala polymorphism affects ex vivo cytokine release and protects against the cytotoxic effects of high ATP-levels.

Authors:  Anke Wesselius; Martijn J L Bours; Ilja C W Arts; Esther H E Theunisz; Piet Geusens; Pieter C Dagnelie
Journal:  BMC Immunol       Date:  2012-12-04       Impact factor: 3.615

View more
  2 in total

Review 1.  Purinergic Signaling in the Regulation of Gout Flare and Resolution.

Authors:  Xiaoling Li; Jie Gao; Jinhui Tao
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

2.  NLRP3 Susceptible Gene Polymorphisms in Patients with Primary Gouty Arthritis and Hyperuricemia.

Authors:  Bei Zhang; Kahaer Mayina; Xiao-Bo Zhang; Mei-Ting Liang; Wu-Jin Chen; Ting-Ting Tian; Ye-Zhou Liu; Yu-Ping Sun
Journal:  Biomed Res Int       Date:  2022-08-23       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.